

Voglibose

Catalog No: tcsc2865



Available Sizes

Size: 50mg

Size: 100mg



Specifications

CAS No:

83480-29-9

Formula:

$C_{10}H_{21}NO_7$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility:

H₂O : ≥ 200 mg/mL (748.28 mM)

Observed Molecular Weight:

267.28


Product Description

Voglibose is an N-substituted derivative of valiolamine, excellent inhibitory activity against α-glucosidases and its action against hyperglycemia and various disorders caused by hyperglycemia.

Target: α-glucosidases

glibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and

sucrose, including maltase and sucrase. The K_i values of Voglibose for sucrase and maltase are about 106 and 105 times smaller than the K_m values for sucrose and maltose [1]. Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats [2]. Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!